BR112014026755A2 - anticorpos contra claudin 18.2 úteis no diagnóstico de câncer - Google Patents
anticorpos contra claudin 18.2 úteis no diagnóstico de câncerInfo
- Publication number
- BR112014026755A2 BR112014026755A2 BR112014026755A BR112014026755A BR112014026755A2 BR 112014026755 A2 BR112014026755 A2 BR 112014026755A2 BR 112014026755 A BR112014026755 A BR 112014026755A BR 112014026755 A BR112014026755 A BR 112014026755A BR 112014026755 A2 BR112014026755 A2 BR 112014026755A2
- Authority
- BR
- Brazil
- Prior art keywords
- claudin
- cancer diagnosis
- antibodies useful
- useful
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EPPCT/EP2012/001991 | 2012-05-09 | ||
PCT/EP2012/001991 WO2013167153A1 (en) | 2012-05-09 | 2012-05-09 | Antibodies useful in cancer diagnosis |
PCT/EP2013/001331 WO2013167259A1 (en) | 2012-05-09 | 2013-05-06 | Antibodies against claudin 18.2 useful in cancer diagnosis |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112014026755A2 true BR112014026755A2 (pt) | 2017-07-11 |
BR112014026755B1 BR112014026755B1 (pt) | 2020-06-16 |
BR112014026755B8 BR112014026755B8 (pt) | 2020-07-07 |
Family
ID=48407427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014026755A BR112014026755B8 (pt) | 2012-05-09 | 2013-05-06 | anticorpos contra claudin 18.2 úteis no diagnóstico de câncer |
Country Status (28)
Country | Link |
---|---|
US (3) | US9512232B2 (pt) |
EP (3) | EP3666796A1 (pt) |
JP (5) | JP6232646B2 (pt) |
KR (3) | KR102308812B1 (pt) |
CN (3) | CN104321345B (pt) |
AR (1) | AR090973A1 (pt) |
AU (3) | AU2013258432B2 (pt) |
BR (1) | BR112014026755B8 (pt) |
CA (1) | CA2869725C (pt) |
CY (1) | CY1122676T1 (pt) |
DK (1) | DK2847225T3 (pt) |
ES (1) | ES2763965T3 (pt) |
HK (1) | HK1202557A1 (pt) |
HR (1) | HRP20192347T1 (pt) |
HU (1) | HUE049171T2 (pt) |
IL (1) | IL235261B (pt) |
LT (1) | LT2847225T (pt) |
MX (1) | MX369740B (pt) |
NZ (2) | NZ700823A (pt) |
PL (1) | PL2847225T3 (pt) |
PT (1) | PT2847225T (pt) |
RS (1) | RS59868B1 (pt) |
RU (1) | RU2661772C2 (pt) |
SG (2) | SG11201406472WA (pt) |
SI (1) | SI2847225T1 (pt) |
UA (2) | UA123943C2 (pt) |
WO (2) | WO2013167153A1 (pt) |
ZA (1) | ZA201407336B (pt) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
MX369276B (es) | 2012-11-13 | 2019-11-04 | Biontech Ag | Agentes para tratamiento de enfermedades cancerosas que expresan claudina. |
WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
WO2014146672A1 (en) | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
WO2016165762A1 (en) | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
WO2016180468A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Claudin-18.2-specific immunoreceptors and t cell epitopes |
KR102046110B1 (ko) * | 2015-12-04 | 2019-11-18 | 주식회사 엘지화학 | 유무기 혼합 페로브스카이트, 이의 제조 방법 및 이를 포함하는 태양 전지 |
CA3030257A1 (en) * | 2016-07-08 | 2018-01-11 | Carsgen Therapeutics Co., Ltd. | Antibody for anti-claudin 18a2 and use thereof |
AU2019232762B2 (en) | 2018-03-08 | 2023-11-16 | Phanes Therapeutics, Inc. | Anti-claudin 18.2 antibodies and uses thereof |
AU2019235033A1 (en) * | 2018-03-14 | 2020-07-30 | Beijing Xuanyi Pharmasciences Co., Ltd. | Anti-claudin 18.2 antibodies |
CN116178555A (zh) * | 2018-05-18 | 2023-05-30 | 礼新医药科技(上海)有限公司 | 抗密蛋白18.2抗体及其用途 |
CN111867630B (zh) * | 2018-06-17 | 2023-10-13 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用 |
CN110606891B (zh) * | 2018-06-17 | 2022-12-06 | 上海健信生物医药科技有限公司 | 一种针对人cldn18.2的抗体分子,抗原结合片段及其医药用途 |
EP3824096A4 (en) * | 2018-07-18 | 2022-04-20 | AskGene Pharma Inc. | NOVEL ANTIBODIES AND METHODS FOR THE PREPARATION AND USE THEREOF |
AU2019314999A1 (en) * | 2018-08-03 | 2021-02-11 | Amgen Inc. | Antibody constructs for CLDN18.2 and CD3 |
CN110857322A (zh) * | 2018-08-22 | 2020-03-03 | 瑞阳(苏州)生物科技有限公司 | 抗人claudin 18.2单克隆抗体及其应用 |
WO2020038404A1 (zh) * | 2018-08-22 | 2020-02-27 | 瑞阳(苏州)生物科技有限公司 | 抗人claudin 18.2单克隆抗体及其应用 |
WO2020043044A1 (zh) * | 2018-08-27 | 2020-03-05 | 南京圣和药业股份有限公司 | 一种抗Claudin18.2抗体及其应用 |
CN112888458A (zh) * | 2018-09-30 | 2021-06-01 | 佧珐药业有限公司 | Cldn18的抗体和化疗药物的联合治疗 |
BR112021007690A2 (pt) * | 2018-10-22 | 2021-08-10 | Shanghai GenBase Biotechnology Co., Ltd. | anticorpo anti-cldn18.2 e uso do mesmo |
SG11202105885WA (en) * | 2018-12-07 | 2021-07-29 | Zlip Holding Ltd | Anti-claudin antibodies and uses thereof |
JP2022516505A (ja) * | 2018-12-28 | 2022-02-28 | スパークス・セラピューティクス・インコーポレイテッド | 癌および他の疾患の治療のための、クローディン18.2に特異的な結合分子、その組成物および方法 |
CN113166246A (zh) * | 2018-12-28 | 2021-07-23 | 四川科伦博泰生物医药股份有限公司 | 一种抗体及其用途 |
CN116333141A (zh) | 2019-01-15 | 2023-06-27 | 浙江道尔生物科技有限公司 | 抗cld18a2纳米抗体及其应用 |
CN109762067B (zh) * | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
CN113645996B (zh) | 2019-02-01 | 2024-04-02 | 新石生物制药有限公司 | 抗claudin 18抗体及其使用方法 |
BR112021019135A2 (pt) * | 2019-04-01 | 2021-11-30 | Jiangsu Hengrui Medicine Co | Anticorpo anticlaudina 18.2 e aplicação do mesmo |
JP2022529703A (ja) * | 2019-04-19 | 2022-06-23 | 康▲諾▼▲亞▼生物医葯科技(成都)有限公司 | 腫瘍治療薬及びその応用 |
CN111944048B (zh) * | 2019-05-16 | 2023-10-03 | 启愈生物技术(上海)有限公司 | 抗cldn抗体及其药物组合物和检测方法 |
WO2020228806A1 (zh) * | 2019-05-16 | 2020-11-19 | 齐鲁制药有限公司 | 针对密蛋白18a2的抗体及其应用 |
KR20220012262A (ko) * | 2019-05-24 | 2022-02-03 | 산유 바이오파마슈티컬스 씨오., 엘티디. | 신형 cldn18.2 결합분자 |
CN111978402B (zh) * | 2019-05-24 | 2022-06-28 | 三优生物医药(上海)有限公司 | 新型cldn18.2结合分子 |
WO2020239005A1 (zh) * | 2019-05-30 | 2020-12-03 | 山东博安生物技术有限公司 | 靶向Claudin18.2的抗体或嵌合抗原受体 |
CN110331199B (zh) * | 2019-06-28 | 2022-04-05 | 国家纳米科学中心 | 用于检测cldn18.2基因表达的分子探针及检测方法 |
WO2021003082A1 (en) * | 2019-07-03 | 2021-01-07 | Phanes Therapeutics, Inc. | Anti-claudin 18.2/anti-cd47 bispecific antibodies and uses thereof |
JP2022545660A (ja) * | 2019-08-20 | 2022-10-28 | スーチョウ トランセンタ セラピューティクス カンパニー,リミテッド | 新規抗cldn18.2抗体 |
TW202124442A (zh) * | 2019-09-13 | 2021-07-01 | 大陸商北京軒義醫藥科技有限公司 | 人源化抗cldn18.2抗體、編碼其的核酸分子、其產生方法、包含其的組合物、試劑盒及其用途 |
CN112574307B (zh) * | 2019-09-29 | 2023-11-28 | 迈威(上海)生物科技股份有限公司 | 抗人Claudin18.2抗体及其应用 |
WO2021088927A1 (en) | 2019-11-05 | 2021-05-14 | Lanova Medicines Limited Company | Antibody-drug conjugates targeting claudin 18.2 |
CN114901696A (zh) | 2019-12-06 | 2022-08-12 | 斯迪安生物技术公司 | 人源化cldn18.2抗体 |
WO2021115303A1 (zh) * | 2019-12-11 | 2021-06-17 | 上海复宏汉霖生物技术股份有限公司 | 一种抗Claudin18.2单克隆抗体、其制备方法及用途 |
CA3162773A1 (en) | 2019-12-23 | 2021-07-01 | Lukas BAMMERT | Tumor-specific claudin 18.2 antibodies |
JP2023510209A (ja) * | 2020-01-03 | 2023-03-13 | クレージュ メディカル カンパニー,リミテッド | 抗クロ―ディン18.2の抗体及びその使用 |
CN111234033B (zh) * | 2020-01-21 | 2021-05-11 | 南京北恒生物科技有限公司 | 多链嵌合抗原受体及其用途 |
KR20220139357A (ko) * | 2020-02-10 | 2022-10-14 | 상하이 에스쿠겐 바이오테크놀로지 컴퍼니 리미티드 | Cldn18.2 항체 및 그의 사용 |
IL296781A (en) * | 2020-03-30 | 2022-11-01 | BioNTech SE | RNA compositions targeting claudin-18.2 |
WO2021238831A1 (en) * | 2020-05-25 | 2021-12-02 | Mabspace Biosciences (Suzhou) Co., Limited | Anti-cldn18.2 antibodies and diagnostic uses thereof |
CN113735974B (zh) * | 2020-05-29 | 2023-10-27 | 杭州邦顺制药有限公司 | 针对Claudin18.2的抗体及其用途 |
CN113854234B (zh) * | 2020-06-30 | 2023-09-08 | 江苏奥赛康生物医药有限公司 | 一种小鼠胰腺癌模型及其构建方法和应用 |
WO2022011531A1 (zh) * | 2020-07-14 | 2022-01-20 | 浙江道尔生物科技有限公司 | 一种抗cld18a2的单域抗体 |
CN111705085B (zh) * | 2020-08-20 | 2020-12-25 | 北京百奥赛图基因生物技术有限公司 | 构建动物模型的方法及应用 |
WO2022100590A1 (zh) * | 2020-11-10 | 2022-05-19 | 齐鲁制药有限公司 | 针对密蛋白18a2的adcc增强型人源化抗体及其应用 |
WO2022122709A1 (en) | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
MX2023007644A (es) | 2020-12-23 | 2023-07-07 | Sotio Biotech A S | Conjugados anticuerpo-farmaco especificos para tumores con claudina 18.2. |
CN116940598A (zh) * | 2021-02-08 | 2023-10-24 | 山东博安生物技术股份有限公司 | 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体 |
WO2022253155A1 (en) * | 2021-05-31 | 2022-12-08 | Shijiazhuang Yiling Pharmaceutical Co., Ltd. | Monoclonal antibodies against cldn18.2 and fc-engineered versions thereof |
CN113687085A (zh) * | 2021-08-27 | 2021-11-23 | 复旦大学附属中山医院 | 一种评估实体肿瘤Claudin18.2蛋白表达的方法和应用 |
CN114751984B (zh) * | 2021-09-03 | 2023-02-14 | 深圳市先康达生命科学有限公司 | 靶向人Claudin18.2蛋白的单克隆抗体及其应用 |
CN117897403A (zh) * | 2021-09-24 | 2024-04-16 | 盛禾(中国)生物制药有限公司 | 一种抗Claudin18.2抗体及其应用 |
WO2023066267A1 (en) * | 2021-10-19 | 2023-04-27 | Biosion Inc. | Antibodies binding cldn18.2 and uses thereof |
CN114836388A (zh) * | 2022-06-07 | 2022-08-02 | 江苏亲科生物研究中心有限公司 | Claudin18.2单克隆抗体及其制备方法和用途 |
Family Cites Families (198)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US6020145A (en) | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
US5589579A (en) | 1994-07-19 | 1996-12-31 | Cytoclonal Pharmaceutics, Inc. | Gene sequence and probe for a marker of non-small cell lung carinoma |
WO2001004311A1 (en) | 1999-07-07 | 2001-01-18 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2000073454A1 (en) | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5677139A (en) | 1995-04-21 | 1997-10-14 | President And Fellows Of Harvard College | In vitro differentiation of CD34+ progenitor cells into T lymphocytes |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
EP1876241A3 (en) | 1996-01-11 | 2008-07-30 | Corixa Corporation | Compositions and methods for the treatment and diagnosis of breast cancer |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US7368531B2 (en) | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
US20070224663A1 (en) | 1997-03-07 | 2007-09-27 | Human Genome Sciences, Inc. | Human Secreted Proteins |
US7411051B2 (en) | 1997-03-07 | 2008-08-12 | Human Genome Sciences, Inc. | Antibodies to HDPPA04 polypeptide |
WO2000078961A1 (en) | 1999-06-23 | 2000-12-28 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030022298A1 (en) | 1997-09-15 | 2003-01-30 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20020127584A1 (en) | 1997-09-18 | 2002-09-12 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030073129A1 (en) | 1998-09-01 | 2003-04-17 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030166104A1 (en) | 1997-09-18 | 2003-09-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030027272A1 (en) | 1997-09-18 | 2003-02-06 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20050196832A1 (en) | 1997-09-18 | 2005-09-08 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030008352A1 (en) | 1997-09-18 | 2003-01-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030032102A1 (en) | 1997-09-18 | 2003-02-13 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7160985B2 (en) | 1997-10-29 | 2007-01-09 | Genentech, Inc. | Pro180 polypeptide |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US20030022835A1 (en) | 1998-04-29 | 2003-01-30 | Genesis Research And Development Corporation Limited | Compositions isolated from skin cells and methods for their use |
US20030040471A1 (en) | 1998-04-29 | 2003-02-27 | Watson James D. | Compositions isolated from skin cells and methods for their use |
JP3428441B2 (ja) | 1998-05-15 | 2003-07-22 | エーザイ株式会社 | タイトジャンクション構成膜蛋白質クローディンファミリー |
US7351543B2 (en) | 1998-06-02 | 2008-04-01 | Genentech, Inc. | Antibodies to a polypeptide encoded by a nucleic acid underexpressed in melanoma |
US7319008B2 (en) | 1998-06-02 | 2008-01-15 | Genentech, Inc. | Nucleic acid underexpressed in melanoma |
EP1084142A4 (en) | 1998-06-11 | 2005-01-19 | Smithkline Beecham Corp | GPR35A RECEIVER |
JP3524061B2 (ja) | 1998-08-04 | 2004-04-26 | ダイアデクスアス・インコーポレーテッド | 肺がんを診断し、モニターし、病期決定し、画像化し、そして処置する新規な方法 |
US20030166132A1 (en) | 1998-08-26 | 2003-09-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7098312B2 (en) | 1998-09-01 | 2006-08-29 | Genetech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20050181478A1 (en) | 1998-09-01 | 2005-08-18 | Baker Kevin P. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
NZ531664A (en) | 1998-09-01 | 2005-07-29 | Genentech Inc | Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family |
US7375184B2 (en) | 1998-09-01 | 2008-05-20 | Genentech, Inc. | PRO1382 polypeptides |
US20030082626A1 (en) | 1998-09-01 | 2003-05-01 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
IL141535A0 (en) | 1998-09-16 | 2002-03-10 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU6143399A (en) | 1998-09-16 | 2000-04-03 | Zymogenetics Inc. | Stomach polypeptide zsig28 |
AU766279B2 (en) * | 1998-10-06 | 2003-10-16 | Curagen Corporation | Novel secreted proteins and polynucleotides encoding them |
US7399834B2 (en) | 1998-10-07 | 2008-07-15 | Genentech, Inc. | Anti-PRO1558 antibodies |
EP1080209A2 (en) | 1998-10-21 | 2001-03-07 | Arch Development Corporation | Methods of treatment of type 2 diabetes |
US7026449B2 (en) | 1999-01-05 | 2006-04-11 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU2883600A (en) | 1999-03-08 | 2000-09-28 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
KR100553300B1 (ko) | 1999-03-08 | 2006-02-20 | 제넨테크, 인크. | 혈관신생 및 심혈관형성의 촉진 또는 억제 방법 |
US7232889B2 (en) | 1999-03-08 | 2007-06-19 | Genentech, Inc. | PRO300 antibodies |
US7507404B2 (en) | 1999-03-08 | 2009-03-24 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
NZ536320A (en) | 1999-03-23 | 2006-04-28 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
CA2383592A1 (en) | 1999-03-31 | 2000-10-05 | Curagen Corporation | 2384891 acids including open reading frames encoding polypeptides; orfx |
US20080286821A1 (en) | 1999-05-14 | 2008-11-20 | Eaton Dan L | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU2215300A (en) | 1999-06-02 | 2000-12-28 | Genentech Inc. | Methods and compositions for inhibiting neoplastic cell growth |
DK1185648T3 (da) | 1999-06-02 | 2007-07-30 | Genentech Inc | Fremgangsmåder og sammensætninger til inhibition af neoplastisk cellevækst |
AU3246100A (en) | 1999-06-02 | 2000-12-28 | Genentech Inc. | Methods and compositions for inhibiting neoplastic cell growth |
ATE449109T1 (de) | 1999-06-15 | 2009-12-15 | Genentech Inc | Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung |
EP1208202A2 (en) | 1999-09-01 | 2002-05-29 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2001027257A1 (en) | 1999-10-14 | 2001-04-19 | The Board Of Trustees Of The University Of Arkansas | Tumor antigen derived gene-16 (tadg-16): a novel extracellular serine protease and uses thereof |
EP1661997A1 (en) | 1999-12-01 | 2006-05-31 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6380362B1 (en) | 1999-12-23 | 2002-04-30 | Genesis Research & Development Corporation Ltd. | Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use |
EP1244784A2 (en) | 2000-01-06 | 2002-10-02 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
WO2001055447A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
AU2001237958A1 (en) | 2000-01-31 | 2001-08-07 | Human Genome Sciences, Inc. | 22 human secreted proteins |
US20030050231A1 (en) | 2000-01-31 | 2003-03-13 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
WO2001055326A2 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
CA2401070A1 (en) | 2000-02-22 | 2001-08-30 | Corixa Corporation | Compositions and methods for diagnosis and therapy of malignant mesothelioma |
AU6802801A (en) | 2000-03-01 | 2001-09-24 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2001070979A2 (en) | 2000-03-21 | 2001-09-27 | Millennium Pharmaceuticals, Inc. | Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer |
US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
JP2003530838A (ja) | 2000-04-12 | 2003-10-21 | ヒューマン ゲノム サイエンシズ インコーポレイテッド | アルブミン融合タンパク質 |
WO2001090357A1 (en) | 2000-05-24 | 2001-11-29 | Genesis Research & Development Corporation Limited | Compositions isolated from skin cells and methods for their use |
WO2002002621A2 (en) | 2000-06-30 | 2002-01-10 | Zymogenetics, Inc. | Mammalian secreted proteins |
AU8470301A (en) | 2000-08-03 | 2002-02-18 | Wim-Van Schooten | Production of humanized antibodies in transgenic animals |
JP2004512029A (ja) | 2000-08-16 | 2004-04-22 | カイロン コーポレイション | ヒト遺伝子および遺伝子発現産物 |
US20030017468A1 (en) | 2000-08-28 | 2003-01-23 | Sei-Yu Chen | Compositions and methods relating to lung specific genes |
ATE549347T1 (de) | 2000-09-08 | 2012-03-15 | Schering Corp | Gene von säugetiere, und damit verbundene reagentien, methoden |
AU2001292728A1 (en) | 2000-09-18 | 2002-03-26 | Thomas Jefferson University | Compositions and methods for identifying and targeting stomach and esophageal cancer cells |
AU3942202A (en) | 2000-11-30 | 2002-06-11 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
WO2002061087A2 (en) | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
WO2002068579A2 (en) | 2001-01-10 | 2002-09-06 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2002066682A2 (en) | 2001-01-29 | 2002-08-29 | Phase-1 Molecular Toxicology, Inc. | Rat toxicologically relevant genes and uses thereof |
CN1516706A (zh) | 2001-02-26 | 2004-07-28 | 阿伦纳药品公司 | 人g蛋白偶联受体的内源性和非内源性形式 |
US20030152939A1 (en) | 2001-04-09 | 2003-08-14 | Glennda Smithson | Novel secreted proteins and polynucleotides encoding them |
US20060084794A1 (en) | 2001-04-12 | 2006-04-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
JP2003000249A (ja) | 2001-05-10 | 2003-01-07 | Daiichi Fine Chemical Co Ltd | クローディンによるMT−MMPsを介したproMMP−2活性化 |
EP1446757A2 (en) | 2001-05-30 | 2004-08-18 | Biomedical Center | In silico screening for phenotype-associated expressed sequences |
US20030148264A1 (en) | 2001-07-06 | 2003-08-07 | Genentech, Inc. | Phage displayed PDZ domain ligands |
US20050282743A1 (en) * | 2001-08-03 | 2005-12-22 | Arbor Vita Corporation | Molecular interactions in cells |
EP1443951A4 (en) | 2001-08-03 | 2006-05-03 | Arbor Vita Corp | MOLECULAR INTERACTIONS IN CELLS |
US20030018172A1 (en) | 2001-12-06 | 2003-01-23 | Genentech, Inc. | Secreted transmembrane polypeptides and nucleic acids encoding the same |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
CA2379661A1 (en) | 2002-03-28 | 2003-09-28 | Kursad Turksen | Paracellular drug delivery system |
WO2003101283A2 (en) | 2002-06-04 | 2003-12-11 | Incyte Corporation | Diagnostics markers for lung cancer |
EP1553975B8 (en) | 2002-09-27 | 2023-04-12 | Xencor, Inc. | Optimized fc variants and methods for their generation |
WO2004029629A1 (en) * | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
ES2744275T3 (es) | 2002-10-17 | 2020-02-24 | Genmab As | Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple |
EP1578365A4 (en) | 2002-11-14 | 2009-09-23 | Arbor Vita Corp | MOLECULAR INTERACTIONS IN NEURONS |
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
EP1430902A1 (en) | 2002-12-20 | 2004-06-23 | Mondobiotech Laboratories Anstalt | Pharmaceutical composition of interferon gamma with molecular diagnostics for the improved treatment of asthma bronchiale |
AU2004204494B2 (en) | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US20050181375A1 (en) | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
CA2528669A1 (en) | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
US20060240441A1 (en) | 2003-10-03 | 2006-10-26 | Bayer Pharmaceuticals Corporation | Gene expression profiles and methods of use |
DE10354601B3 (de) | 2003-11-21 | 2005-06-23 | Chiropro Gmbh | Gelenkprothese für Fingerglieder |
WO2005052182A2 (en) | 2003-11-26 | 2005-06-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | A method of analyzing plasma membrane protein content of cells |
US7858322B2 (en) | 2003-12-23 | 2010-12-28 | Nono, Inc. | Method of determining inhibition of binding to TRPM7 protein |
WO2005076939A2 (en) | 2004-02-09 | 2005-08-25 | University Of Kentucky Research Foundation | Assay and method for diagnosing and treating alzheimer’s disease |
CA2557181A1 (en) | 2004-02-26 | 2005-09-09 | Ohio University | Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in muscle cells |
US20050255041A1 (en) | 2004-05-13 | 2005-11-17 | Arius Research, Inc. | Cancerous disease modifying antibodies |
DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
US20060141528A1 (en) | 2004-05-21 | 2006-06-29 | Aebersold Rudolf H | Compositions and methods for quantification of serum glycoproteins |
WO2006023121A1 (en) | 2004-07-27 | 2006-03-02 | Ohio University | Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in white adipose tissue (13) |
DE102004042822A1 (de) | 2004-08-31 | 2006-03-16 | Technische Universität Dresden | Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen |
FR2876705B1 (fr) | 2004-10-19 | 2008-12-12 | Biomerieux Sa | Procede pour le diagnostic d'une intolerance a l'aspirine |
US20070072175A1 (en) | 2005-05-13 | 2007-03-29 | Biogen Idec Ma Inc. | Nucleotide array containing polynucleotide probes complementary to, or fragments of, cynomolgus monkey genes and the use thereof |
US7595151B2 (en) | 2005-07-01 | 2009-09-29 | Arbor Vita Corporation | Methods and compositions for diagnosis and treatment of influenza |
WO2007021423A2 (en) | 2005-08-15 | 2007-02-22 | Genentech, Inc. | Gene disruptions, compositions and methods relating thereto |
WO2007027867A2 (en) * | 2005-08-31 | 2007-03-08 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
BRPI0616090A2 (pt) | 2005-09-19 | 2011-06-07 | Veridex Llc | métodos e materiais para identificação da origem de um carcinoma de origem primária desconhecida |
US20070099251A1 (en) | 2005-10-17 | 2007-05-03 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
CA2637988A1 (en) * | 2006-02-10 | 2007-11-29 | Genentech, Inc. | Anti-fgf19 antibodies and methods using same |
CA2647430A1 (en) | 2006-03-29 | 2007-10-11 | Genentech, Inc. | Diagnostics and treatments for tumors |
WO2008013948A2 (en) | 2006-07-27 | 2008-01-31 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
WO2008021290A2 (en) | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
WO2008021115A2 (en) | 2006-08-14 | 2008-02-21 | The Brigham And Women's Hospital, Inc. | Diagnostic tests using gene expression ratios |
US20090258442A1 (en) * | 2006-08-31 | 2009-10-15 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
WO2008082730A2 (en) | 2006-09-19 | 2008-07-10 | Novartis Ag | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors |
EP2087110A2 (en) | 2006-10-11 | 2009-08-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Influenza targets |
US20090018031A1 (en) | 2006-12-07 | 2009-01-15 | Switchgear Genomics | Transcriptional regulatory elements of biological pathways tools, and methods |
AU2007333106A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | miR-20 regulated genes and pathways as targets for therapeutic intervention |
US20100021886A1 (en) | 2007-02-01 | 2010-01-28 | Yixin Wang | Methods and Materials for Identifying the Origin of a Carcinoma of Unknown Primary Origin |
EP2145902A3 (en) | 2007-04-19 | 2010-09-29 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
WO2008154333A2 (en) | 2007-06-08 | 2008-12-18 | Asuragen, Inc. | Mir-34 regulated genes and pathways as targets for therapeutic intervention |
US20100292303A1 (en) | 2007-07-20 | 2010-11-18 | Birrer Michael J | Gene expression profile for predicting ovarian cancer patient survival |
WO2009035497A2 (en) | 2007-08-08 | 2009-03-19 | Savidge Tor C | Disease related cysteine modifications and uses thereof |
EP2036987A1 (en) | 2007-09-17 | 2009-03-18 | Siemens Healthcare Diagnostics GmbH | Molecular markers for tumor cell content in tissue samples |
WO2009047362A2 (en) | 2007-10-12 | 2009-04-16 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Method for opening tight junctions |
WO2009102367A2 (en) | 2007-11-19 | 2009-08-20 | The Regents Of The University Of Colorado | Tight junction protein modulators and uses thereof |
WO2009148593A1 (en) | 2008-06-02 | 2009-12-10 | Nsabp Foundation, Inc. | Identification and use of prognostic and predictive markers in cancer treatment |
EP2303926A1 (en) | 2008-06-20 | 2011-04-06 | Oklahoma Medical Research Foundation | Immunogenic memapsin 2 -secretase peptides and methods of use |
US20110190380A1 (en) | 2008-10-23 | 2011-08-04 | Elena Feinstein | Methods for delivery of sirna to bone marrow cells and uses thereof |
CN101381524A (zh) | 2008-10-24 | 2009-03-11 | 南开大学 | 单层氧化石墨与水溶性高分子增强复合材料 |
US20110286916A1 (en) | 2008-11-20 | 2011-11-24 | Jose Miguel Aste-Amezaga | Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use |
GB0904957D0 (en) | 2009-03-23 | 2009-05-06 | Univ Erasmus Medical Ct | Tumour gene profile |
US20120028816A1 (en) | 2009-03-31 | 2012-02-02 | Warren Stephen T | Methods and systems for screening for and diagnosing dna methylation associated with autism spectrum disorders |
CN101584860A (zh) * | 2009-04-27 | 2009-11-25 | 西安杰诺瓦生物科技有限公司 | 重组人Claudin18.2肿瘤疫苗及其制备方法 |
AU2010302955A1 (en) | 2009-10-01 | 2012-05-17 | Chipdx Llc | System and method for classification of patients |
JP2013512000A (ja) | 2009-12-01 | 2013-04-11 | コンペンディア バイオサイエンス, インコーポレイテッド | 癌の分類 |
WO2011113546A1 (en) * | 2010-03-16 | 2011-09-22 | Biontech Ag | Tumor vaccination involving a humoral immune response against self-proteins |
EP2366709A1 (en) | 2010-03-16 | 2011-09-21 | BioNTech AG | Tumor vaccination involving a humoral immune response against self-proteins |
US8945847B2 (en) | 2010-05-24 | 2015-02-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and kits for ascertaining biosafety of an agent |
CN103119176A (zh) | 2010-06-07 | 2013-05-22 | 霍夫曼-拉罗奇有限公司 | 用于预测对白介素-6受体抑制性单克隆抗体药物治疗的响应的基因表达标记 |
US8454385B2 (en) | 2010-06-22 | 2013-06-04 | John Mezzalingua Associates, LLC | Coaxial cable connector with strain relief clamp |
WO2012070014A2 (en) | 2010-11-26 | 2012-05-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Identification of novel cell surface markers for pancreatic progenitor cells and definite endodermal cells |
AU2012206163B2 (en) | 2011-01-12 | 2013-11-14 | Morinaga Milk Industry Co., Ltd. | Method for screening for diet providing production of milk having immunoregulatory action |
DE102011005235B4 (de) | 2011-03-08 | 2017-05-24 | Sirs-Lab Gmbh | Verfahren zum Identifizieren einer Teilmenge von Polynucleotiden aus einer dem Humangenom entsprechenden Ausgangsmenge von Polynucleotiden zur in vitro Bestimmung eines Schweregrads der Wirtsantwort eines Patienten |
AU2013243946A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of membrane proteins |
WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
WO2013174403A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
WO2014025198A2 (ko) | 2012-08-09 | 2014-02-13 | 주식회사 한독 | Lfa3 변이체 및 상기 변이체 또는 lfa3 cd2 결합영역과 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도 |
WO2014025199A2 (ko) | 2012-08-09 | 2014-02-13 | 주식회사 한독 | 스테필로코칼 엔테로톡신 유래의 초항원 변이체 및 이에 표적 특이적 폴리펩타이드가 연결된 융합단백질 및 그 용도 |
US20150299797A1 (en) | 2012-08-24 | 2015-10-22 | University Of Utah Research Foundation | Compositions and methods relating to blood-based biomarkers of breast cancer |
US20140073524A1 (en) | 2012-09-07 | 2014-03-13 | Institute For Systems Biology | Markers and methods for detecting posttraumatic stress disorder (ptsd) |
US9856532B2 (en) | 2012-09-07 | 2018-01-02 | Institute For Systems Biology | Markers and methods for detecting posttraumatic stress disorder (PTSD) |
-
2012
- 2012-05-09 WO PCT/EP2012/001991 patent/WO2013167153A1/en active Application Filing
-
2013
- 2013-05-06 CN CN201380024247.0A patent/CN104321345B/zh active Active
- 2013-05-06 PL PL13721596T patent/PL2847225T3/pl unknown
- 2013-05-06 KR KR1020147031431A patent/KR102308812B1/ko active IP Right Grant
- 2013-05-06 CA CA2869725A patent/CA2869725C/en active Active
- 2013-05-06 LT LTEP13721596.8T patent/LT2847225T/lt unknown
- 2013-05-06 MX MX2014013542A patent/MX369740B/es active IP Right Grant
- 2013-05-06 SG SG11201406472WA patent/SG11201406472WA/en unknown
- 2013-05-06 SI SI201331647T patent/SI2847225T1/sl unknown
- 2013-05-06 NZ NZ700823A patent/NZ700823A/en not_active IP Right Cessation
- 2013-05-06 CN CN202210243984.0A patent/CN114573697A/zh active Pending
- 2013-05-06 RS RS20200006A patent/RS59868B1/sr unknown
- 2013-05-06 HU HUE13721596A patent/HUE049171T2/hu unknown
- 2013-05-06 US US14/397,244 patent/US9512232B2/en active Active
- 2013-05-06 DK DK13721596.8T patent/DK2847225T3/da active
- 2013-05-06 EP EP19210903.1A patent/EP3666796A1/en not_active Withdrawn
- 2013-05-06 WO PCT/EP2013/001331 patent/WO2013167259A1/en active Application Filing
- 2013-05-06 EP EP13721596.8A patent/EP2847225B1/en active Active
- 2013-05-06 ES ES13721596T patent/ES2763965T3/es active Active
- 2013-05-06 KR KR1020217031155A patent/KR102506364B1/ko active IP Right Grant
- 2013-05-06 RU RU2014149332A patent/RU2661772C2/ru active
- 2013-05-06 CN CN201810016956.9A patent/CN108047331B/zh active Active
- 2013-05-06 JP JP2015510676A patent/JP6232646B2/ja active Active
- 2013-05-06 NZ NZ718280A patent/NZ718280A/en not_active IP Right Cessation
- 2013-05-06 AU AU2013258432A patent/AU2013258432B2/en active Active
- 2013-05-06 PT PT137215968T patent/PT2847225T/pt unknown
- 2013-05-06 BR BR112014026755A patent/BR112014026755B8/pt active IP Right Grant
- 2013-05-06 KR KR1020237007205A patent/KR20230035697A/ko active IP Right Grant
- 2013-05-06 EP EP22152178.4A patent/EP4036119A1/en active Pending
- 2013-05-06 SG SG10201606048PA patent/SG10201606048PA/en unknown
- 2013-05-06 UA UAA201711510A patent/UA123943C2/uk unknown
- 2013-05-07 AR ARP130101567A patent/AR090973A1/es unknown
- 2013-06-05 UA UAA201413190A patent/UA116445C2/uk unknown
-
2014
- 2014-10-09 ZA ZA2014/07336A patent/ZA201407336B/en unknown
- 2014-10-22 IL IL235261A patent/IL235261B/en active IP Right Grant
-
2015
- 2015-03-23 HK HK15102925.9A patent/HK1202557A1/xx unknown
-
2016
- 2016-08-03 US US15/227,565 patent/US10053512B2/en active Active
-
2017
- 2017-08-16 AU AU2017216513A patent/AU2017216513B2/en active Active
- 2017-10-02 JP JP2017192778A patent/JP6514294B2/ja active Active
-
2018
- 2018-07-17 US US16/037,759 patent/US11976130B2/en active Active
-
2019
- 2019-04-11 JP JP2019075579A patent/JP6878491B2/ja active Active
- 2019-08-28 AU AU2019222874A patent/AU2019222874B2/en active Active
- 2019-12-30 HR HRP20192347TT patent/HRP20192347T1/hr unknown
-
2020
- 2020-01-08 CY CY20201100015T patent/CY1122676T1/el unknown
-
2021
- 2021-04-28 JP JP2021075743A patent/JP2021138700A/ja active Pending
-
2023
- 2023-05-17 JP JP2023081407A patent/JP2023109883A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014026755B8 (pt) | anticorpos contra claudin 18.2 úteis no diagnóstico de câncer | |
CY1122278T1 (el) | Αντι il-36r αντισωματα | |
CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
WO2014160499A3 (en) | Methods and compositions for detecting pancreatic cancer | |
EA201390933A1 (ru) | Антитела против мезотелина и иммуноконъюгаты | |
CR20120371A (es) | Antagonistas de pcsk9 | |
WO2014160160A3 (en) | Antibody drug conjugates and corresponding antibodies | |
CR20140529A (es) | Anticuerpos e inmunoconjugados contra ly6e y métodos de uso | |
MX2022010324A (es) | Sitios especificos para modificar anticuerpos para hacer inmunoconjugados. | |
EA201591750A1 (ru) | Антитела против b7-h4 и иммуноконъюгаты | |
WO2014124334A3 (en) | Transthyretin antibodies and uses thereof | |
MX336682B (es) | Anticuerpos contra csf-1r humanos y usos de los mismos. | |
MA34091B1 (fr) | Anticorps anti-cd40 | |
EA201590173A1 (ru) | Иммуноконъюгаты, содержащие антитела к cd22 | |
MX356337B (es) | Anticuerpos contra csf-1r humano y sus usos. | |
UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
MX2014012978A (es) | Regiones de anticuerpo modificado y sus usos. | |
EA201291065A1 (ru) | Антитела против vla-4 | |
WO2014197835A3 (en) | Methods and compositions for the treatment of cancer | |
WO2013106747A3 (en) | Methods and compositions for the treatment and diagnosis of thyroid cancer | |
MX2022007706A (es) | Anticuerpos utiles en diagnosis de cancer. | |
BR112014001979A2 (pt) | uso do anticorpo i-3859 para a detecção e diagnóstico de câncer | |
SA518391028B1 (ar) | Cd37 أجسام مضادة واختبارات للكشف عن | |
TR201910413T4 (tr) | Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler. | |
MX2019002818A (es) | Metodos para detectar anticuerpos neutralizantes anti-leptina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B65X | Notification of requirement for priority examination of patent application | ||
B65Y | Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117) | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI. |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/05/2013, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2580 DE 16/06/2020 QUANTO AO INVENTOR. |
|
B25D | Requested change of name of applicant approved |
Owner name: TRON - TRANSLATIONALE ONKOLOGIE AN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ GEMEINNUETZIGE GMBH (DE) ; GANYMED PHARMACEUTICALS GMBH (DE) |
|
B25D | Requested change of name of applicant approved |
Owner name: GANYMED PHARMACEUTICALS GMBH (DE) ; TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAET MAINZ GEMEINNUETZIGE GMBH (DE) |
|
B25A | Requested transfer of rights approved |
Owner name: TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAET MAINZ GEMEINNUETZIGE GMBH (DE) ; ASTELLAS PHARMA INC. (JP) |